Tony Arulanandam
Chief Executive Officer Synaptimmune Therapeutics
Tony Arulanandam, DVM, PhD, is CEO /Founder Synaptimmune Therapeutics, Developing the next generation “Conditionally active and Costimulatory T cell engagers (TCE)” for Autoimmune and Solid tumor indications.
He is also the Co-Founder of NextPoint therapeutics, an MPM capital-funded novel IO checkpoint inhibitor, TCE and ADC clinical stage company. Previously Senior Vice President and Head of R&D at Cytovia Therapeutics and held senior management positions at PTC, Alexion, Regeneron, Biogen, Dyax and Ares-Serono developing immunotherapys for autoimmunity and cancer. He is an immunologist with 20+ years of research and development experience developing multiple immunotherapies for autoimmune/inflammatory diseases and cancer including 3 BLAs (TysabriTM, KevzaraTM, DupixentTM ) and multiple INDs.
Seminars
- Using a SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats of bispecifics/ multispecifics compared to other drug modalities?
- In which cases are bispecifics/multispecifics being prioritized for autoimmune and immunology versus oncology?
- What datapoints are being assessed when it comes to bispecifics/multispecifics from a data package perspective for approval and backing from pharma?
- What data is lacking across the board for bispecifics/multispecifics?
- How are novel versus derisked targets being assessed, and what weighting/value is placed on safety and efficacy data, versus other data points?
- What stimulates interest around bispecific/multispecific assets versus platform technologies that generate target, construct and format menus?
- Conditional CD3 activation via hidden CD3 binder in TROY-Ig scaffold mitigates cytokine release
- CD2 costimulation and CD58 adhesion lowers the threshold for CD3 activation in T-cells
- CD2 costimulation and conditional CD3 activation TROY-Ig scaffold enables increased anti-tumor efficacy in solid tumor microenvironment
